Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes

A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SHR117887 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients

SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SHR117887 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control

Inclusion Criteria:

• Patients diagnosed with type 2 diabetes mellitus
• Patients have been treated with metformin for at least 8 weeks and be on a stable dose of at least 1500mg daily prior to the screening visit
• HbA1C：≥7.5% and ≤11.0% at screeing visit and at the end of run-in period
• Age:≥20 and ≤70 years
• BMI(body mass index):≥20 and ≤35 kg/m2

Exclusion Criteria:

-